Researchers at Lund University in Sweden headed by Professor Singerup Linse and Erik Helistrand have recently identified a molecular mechanism behind the crucial step in Alzheimer’s that leads to the death of brain cells. The neurological disease is associated, as a general statement, with memory loss and changes in personality. The research at Lund […]
According to Northwestern Medicine Research, new experimental molecules have great promise in targeting enzymes in the brain that prevent memory loss in Alzheimer’s disease. Developed in D. Martin Watterson’s laboratory, the molecules halted memory loss and were able to fix damaged communication between brain cells in mice. Researchers identified and targeted a key enzyme: a […]
Researchers at Houston Methodist’s Nantz National Alzheimer Center are studying an investigational drug to slow brain cell deterioration in patients with mild to moderate Alzheimer’s disease. T-817MA focuses on preventing brain cell loss and slowing disease progression, where current treatment options like Donepezil, Rivastigmine, and Memantine only treat the symptoms. The scientists want to know […]
A study conducted recently at the Univeraity of California- San Francisco published online in JAMA Internal Medicine. The research was focused in on finding a close link between diabetes and dementia. According to the journal, diabetic patients with low blood sugar may have an increased risk of developing dementia, and patients with dementia or other […]
Researchers at Sanford-Burnham Medical Research Institute have developed the first experimental drug named NitroMemantine that boosts brain synapses lost to Alzheimer’s disease. The medication combines two FDA-approved drugs to stop destructive cascades within the brain, which destroys the connections between neurons and ultimatly leads to memory loss and a decline in cognition. Dr. Stuart A. […]
Researchers at the Michigan Alzheimer’s Disease Center discovered that flavored ECGC, or epigallocatechi-3-gallate, found in green tea could bind to the toxic protein beta-amyloid and prevent its build-up. When ECGC binds to the protein, it is able to change beta-amyloid’s properties. Dr. Mi Hee Lim, lead researcher of the study, found that ECGC bonded to […]
Researchers at Duke University have identified a new type of neuron within the adult brain capable of directing stem cells to make new neurons. The experiments are preliminary, but the hope is that the brain one day could be healing itself from within. Chay Kuo, M.D, Ph.D., an assistant professor of cell biology, neurobiology, and […]
Mayo clinic researchers demonstrated within a mouse model that a synthetic peptide carrier works to deliver brain cancer chemotherapy drugs, as well as neurological medications. Neuroscientist Gobinda Sarkar, Ph.D, of the Mayo Clinic and corresponding author of the study discussed that they were able to transport eight different molecules, and much less disruptively through the […]
Amino Acids Improve Sleep in Mice with Traumatic Brain Injury A study by Oregon Health and Science University, published in Science Translational Medicine, discovered a way to fix sleep disturbances in mice suffering from traumatic brain injury. These results are important, because people commonly experience long-term and severe sleep and wakefulness issues after suffering concussions, […]
A study released in the January 9th issue of the Journal of Neurology suggests that nicotine patches may help individuals with early memory loss. Dr. Paul Newhouse, a professor of psychiatry at Vanderbilt University Medical Center, led a study which showed that six months of nicotine patch treatment among patients who had mild cognitive impairment […]
ALZHEIMER’S DISEASE A research study is being conducted in our area to evaluate an investigational medication for Alzheimer’s disease. Qualified participants may receive: – Study related medical care – Study medication – Compensation for time and travel Please call now for more info: Dr. Andrew Keegan 941-256-8018 ext. 353 The Roskamp Institute Memory Clinic and […]
Media Contact: Cheryl Rindfleisch, Roskamp Institute 941-256-8018 x356 firstname.lastname@example.org or Jeffree Itrich 858-622-5827 email@example.com May 10, 2010 Investigational Immune Intervention Slows Brain Atrophy in Alzheimer’s Patients 18-Month Phase 2 Study is First to Show Combined Benefits of IGIV on Clinical Outcomes and Brain-Imaging Measures Phase 3 Study Now Enrolling Participants at the Roskamp Institute in […]
Dr. Cheryl Luis of the Roskamp Institute was awarded a New Investigator Research Grant from the Alzheimer’s Association in 2009. She is studying the potential usefulness of a blood test in combination with a paper and pencil memory test for early detection of cognitive decline in older adults. Additional research volunteers are needed. If you […]
The James & Esther King Biomedical Research Program has awarded Dr. Daniel Paris of The Roskamp Institute the Small Business Technology Transfer Grant for $100,000 to conduct a research project titled: “Treatment of Lung Adenocarcinoma and Metastasis by Anti-angiogenic Fragments of Abeta.” The Institute has previously shown that the Abeta peptite can help inhibit the […]
As reported in today’s Bradenton Herald, the Roskamp Institute is searching for clinical trial participants for two potential Alzheimer’s disease treatments. Bapineuzumab and ELND005 are being tested; both hope to successfully remove plaque from the brain which helps cause the condition. For more information please visit the Roskamp Institute Clinical Trial Division web page.
The Sarasota Herald-Tribune reports today in an article titled “In quest to unravel Alzheimer’s, drug may soon be tested locally” that The Roskamp Institute is planning to conduct a clinical trial of a potential Alzheimer’s disease treatment this summer. It will occur in the Sarasota, Florida area, where the Institute is located.
The Roskamp Institute announced on December 14, 2007 that an independent Tokyo Medical University study validates its ongoing research into the Alzheimer’s Disease drug Nilvadipine which is in testing. The International Journal of Geriatric Psychiatry details the results of study that suggests that Nilvadipine can prevent in people with memory problems the onset of Alzheimer’s. […]
The recent findings showing that certain anti-hypertensive (drugs which lower hypertension) drugs may be helpful in Alzheimer’s disease, is consistent with the work of the Roskamp Institute. The Roskamp Institute has been conducting pioneering research in this area for several years and is currently conducting a clinical trial in Europe to test whether a […]
The Traumatic Brain Injury Program at the Roskamp Institute Among the soldiers who survive conflicts in Iraq and Afghanistan, the traumatic brain injuries account for a larger proportion of their casualties than in any other US war in recent history. According to the Joint Theater Trauma Registry, established by the U.S. Army Institute of Surgical […]
The US Federal Government’s site ClinicalTrials.gov is an excellent source of information about various medical tests.
In an upbeat article from February about the prospects of those who suffer from Down Syndrome and Alzheimer’s Disease, Stephanie Hayes of The St. Petersburg Times explains how the Roskamp Institute‘s trial of a new treatment for Alzheimer’s could further improve the life of those who have the disease.
Last year on World Alzheimer’s Day — September 21, 2006 — the Roskamp Institute helped celebrate a day by starting a clinical trial, and for the first time the trial is on a product of Roskamp’s own work. Hopefully, this study will yield positive results for Alzheimer’s research.
The Roskamp Institute is helping with trials for the Alzheimer’s drug Nilvadipine to get it approved for use in the United States, and the Herald Tribune in Florida reports that the human trials are going well. If all goes well with Nilvadipine, we’re one step closer to making life much better for those who suffer […]
We have just put out a press release announcing the Roskamp Institute’s participation in a multiple sclerosis study. Here’s a quote from Michael Mullan: “We are looking for volunteers to participate in this pharmaceutical sponsored research study to assess the effectiveness and safety of the investigational drug fingolimod, used to treat patients with relapsing-remitting MS,” […]
One of the key aspects of our research at the Roskamp Institute is clinical trials. Without qualified volunteers, our work is impossible. We are currently recruiting volunteers for our clinical trials, which are run by our Scientific Director, Michael Mullan, MBBS, Ph.D. We are currently recruiting for clinical trials on the following diseases. Alzheimer’s Disease […]